103499256
赞了
$Arbutus Biopharma (ABUS.US)$
Arbutus生物制药和Barinthus Bio宣布了来自Im-PROVE II试验的新数据，显示尼伦单抗的加入增加了慢性乙型肝炎患者中HBsAg消失的比例。
arbutus biopharma和Barinthus Bio宣布了慢性乙型肝炎治疗II期Im-PROVE II试验的新初步数据。
该研究评估了imdusiran、VTP-300和低剂量nivolumab的结合。
关键发现显示，接受三联疗法的参与者中有23%
Arbutus生物制药和Barinthus Bio宣布了来自Im-PROVE II试验的新数据，显示尼伦单抗的加入增加了慢性乙型肝炎患者中HBsAg消失的比例。
arbutus biopharma和Barinthus Bio宣布了慢性乙型肝炎治疗II期Im-PROVE II试验的新初步数据。
该研究评估了imdusiran、VTP-300和低剂量nivolumab的结合。
关键发现显示，接受三联疗法的参与者中有23%
已翻译
1
103499256
赞了
$Arbutus Biopharma (ABUS.US)$
arbutus biopharma的Imdusiran与干扰素短程联合治疗慢性乙型肝炎（cHBV）患者时取得功能性治愈效果
arbutus biopharma（ABUS）宣布从其Im-PROVE I第2a期临床试验中获得了让人振奋的结果，该试验针对慢性乙型肝炎病毒（cHBV）的RNAi疗法imdusiran。
与24周的聚乙二醇干扰素和核苷（t）类似物治疗相结合，治疗在基线为…的患者中实现了50%的功能性治愈率（6名患者中3名）。
arbutus biopharma的Imdusiran与干扰素短程联合治疗慢性乙型肝炎（cHBV）患者时取得功能性治愈效果
arbutus biopharma（ABUS）宣布从其Im-PROVE I第2a期临床试验中获得了让人振奋的结果，该试验针对慢性乙型肝炎病毒（cHBV）的RNAi疗法imdusiran。
与24周的聚乙二醇干扰素和核苷（t）类似物治疗相结合，治疗在基线为…的患者中实现了50%的功能性治愈率（6名患者中3名）。
已翻译
1
103499256
评论了
哈哈哈。所以，我在71时全部出局。这对我来说足够赚取50%。
103499256
评论了
![[empty]](https://static.moomoo.com/node_futunn_nnq/assets/images/folder.5c37692712.png)
![[error]](https://static.moomoo.com/node_futunn_nnq/assets/images/no-network.991ae8055c.png)
![[loading]](data:image/svg+xml;base64,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)